Education
About Us
Working with TipRanks
Follow Us
Amphastar Pharmaceuticals (AMPH)
NASDAQ:AMPH
Earnings Data
Report Date
May 13, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.72Last Year’s EPS
0.74Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a cautiously optimistic outlook: the company reported strong product-level growth (notably BAQSIMI and Primatene MIST), multiple FDA approvals including a product with 180-day exclusivity (AMP-007), a meaningful proprietary pipeline expansion and strong operating cash flow and cash reserves to fund growth and buybacks. Offsetting these positives are significant declines and pricing pressure in legacy products (notably glucagon down 45%), expected margin compression in 2026 due to pricing and input-cost pressures, increased operating spend (G&A and R&D), and modest full-year revenue decline of 2%. Overall, strategic wins and cash strength provide upside potential, but near-term margin and legacy-product headwinds temper the outlook.Company Guidance
Full-Year Revenue and Key Product Contributions
Net revenues for FY2025 were $719.9 million. BAQSIMI generated $185.4 million, up 12% year-over-year, and Primatene MIST delivered $108.7 million, up 7% year-over-year. Newer products contributed, including $4.4 million from iron sucrose following its August launch.
FDA Approvals and Exclusive Launch Opportunity
FDA approvals in 2025 included iron sucrose, teriparatide and ipratropium bromide HFA (AMP-007). AMP-007 was granted 180 days of generic exclusivity as first Paragraph IV filer; commercial launch expected early Q2 2026, representing a meaningful near-term respiratory growth driver (IQVIA Atrovent market ~$112M).
Operating Cash Flow and Balance Sheet Strength
Operating cash flow for the full year was $156.1 million. The company reported over $300 million in cash and short-term investments and an ongoing share buyback program (historical repurchases ~ $75 million in the prior year, ~$15 million remaining on current authorization).
Q4 BAQSIMI Performance
BAQSIMI sales in Q4 grew 12% year-over-year to $46.7 million, driven by higher U.S. unit volumes and transition to direct global distribution.
Other Product Growth and Market Demand
Other pharmaceutical product revenues rose 8% in Q4 to $62.4 million, primarily due to increased sales of albuterol and the recently launched iron sucrose; albuterol also showed strong market-driven growth.
Pipeline Expansion into High-Value Therapeutic Areas
Expanded proprietary pipeline with three novel peptides (oncology and ophthalmology), a synthetic corticotropin program (immunology) and programs AMP-105/109/110/107; company estimates these collectively open >$60 billion in addressable market opportunity.
Near- and Mid-Term High-Value Programs on Track
Insulin aspart BLA (AMP-004) and GLP-1 ANDA (AMP-018) are progressing through regulatory proceedings with anticipated commercialization in 2027, representing meaningful near- and midterm value drivers.
Manufacturing Capacity Expansion
Planned Rancho Cucamonga expansion to quadruple production capacity, enhancing scalability and supply reliability to support proprietary and complex generics commercialization; capital spending to ramp in 2026 financed from operations.
AMPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AMPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $26.49 | $20.23 | -23.63% |
Nov 06, 2025 | $24.23 | $24.03 | -0.83% |
Aug 07, 2025 | $21.62 | $23.81 | +10.13% |
May 07, 2025 | $24.43 | $24.65 | +0.90% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Amphastar Pharmaceuticals (AMPH) report earnings?
Amphastar Pharmaceuticals (AMPH) is schdueled to report earning on May 13, 2026, After Close (Confirmed).
What is Amphastar Pharmaceuticals (AMPH) earnings time?
Amphastar Pharmaceuticals (AMPH) earnings time is at May 13, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AMPH EPS forecast?
AMPH EPS forecast for the fiscal quarter 2026 (Q1) is 0.72.